Open Clinical Trials

USOR #17188

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

SYD985 (antibody-drug conjugate) versus Physician’s Choice Treatment

Protocol Number: USOncology 17027 (
A Multi-centre, Open-Label, Randomized Clinical Trial Comparing the Efficacy and Safety of the Antibody-Drug Conjugate SYD985 to Physician’s Choice in Patients with HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

WordPress Appliance - Powered by TurnKey Linux